Investors & Media

Aug 6, 2021 /

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Aug 6, 2021 / Aug 6, 2021 /

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Recent News

5/25/21

BELLUS Health to Participate in the Jefferies Virtual Healthcare Conference
LAVAL, Quebec --(BUSINESS WIRE)--May 25, 2021-- BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic cough (“RCC”) and other hypersensitization-related disorders,...
Read More
5/12/21

BELLUS Health to Participate in the 2021 RBC Capital Markets Global Healthcare Conference
LAVAL, Quebec --(BUSINESS WIRE)--May 12, 2021-- BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic cough ("RCC") and other hypersensitization-related disorders,...
Read More
5/10/21

BELLUS Health Reports First Quarter 2021 Financial Results and Business Highlights
- Phase 2b SOOTHE and Phase 2a BLUEPRINT clinical trials on track, with topline results expected Q4 2021 - - Ended quarter with US$81.9 million in cash, cash equivalents and short-term investments; current cash position expected to be sufficient to fund operating plan until end of 2022 - LAVAL,...
Read More